Minsi Zhang1, T Jonathan Yang1, Neil B Desai1, Deborah DeLair2, Marisa A Kollmeier1, Vicky Makker3, Mario M Leitao4, Nadeem R Abu-Rustum4, Kaled M Alektiar5. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY. 4. Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY. 5. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: alektiak@mskcc.org.
Abstract
PURPOSE: The treatment paradigm for uterine clear cell carcinoma is often linked to serous carcinoma. This study compares oncologic outcomes between women with uterine clear cell and serous carcinoma. METHODS AND MATERIALS: We reviewed 114 women with stage I-II uterine clear cell carcinoma (n = 17, 15%) or serous carcinoma (n = 97, 85%) who underwent hysterectomy and salpingo-oophorectomy at our institution from April 1992 to December 2011; 86 (76%) had stage IA, 14 (12%) had stage IB, and 14 (12%) had stage II disease. Median followup was 57 months. RESULTS: Patients with uterine clear cell and serous carcinoma did not differ significantly by age ≥60 years, stage, or rate of lymphovascular invasion. There was no difference in the number of patients with clear cell or serous histology who received adjuvant radiotherapy (71% vs. 84%, respectively; p = 0.31); however, significantly fewer patients with clear cell histology received adjuvant chemotherapy (35% vs. 67%, respectively; p = 0.02). At 5 years, there were no significant differences in disease-free survival (94% vs. 84%, respectively; p = 0.27), disease-specific survival (100% vs. 92%, respectively; p = 0.20), or overall survival (100% vs. 89%, respectively; p = 0.34). The differences in chemotherapy utilization did not impact pattern of relapse, specifically peritoneal spread (7% vs. 6%, respectively; p = 0.92) or other distant sites (0% vs. 9%, respectively; p = 0.17). CONCLUSIONS: Oncologic outcomes and recurrence patterns of women with stage I-II uterine clear cell carcinoma compared favorably with those of women with serous carcinoma, despite significantly less adjuvant chemotherapy use. Potential reduction in adjuvant therapy in women with clear cell carcinoma should be studied prospectively.
PURPOSE: The treatment paradigm for uterine clear cell carcinoma is often linked to serous carcinoma. This study compares oncologic outcomes between women with uterine clear cell and serous carcinoma. METHODS AND MATERIALS: We reviewed 114 women with stage I-II uterine clear cell carcinoma (n = 17, 15%) or serous carcinoma (n = 97, 85%) who underwent hysterectomy and salpingo-oophorectomy at our institution from April 1992 to December 2011; 86 (76%) had stage IA, 14 (12%) had stage IB, and 14 (12%) had stage II disease. Median followup was 57 months. RESULTS:Patients with uterine clear cell and serous carcinoma did not differ significantly by age ≥60 years, stage, or rate of lymphovascular invasion. There was no difference in the number of patients with clear cell or serous histology who received adjuvant radiotherapy (71% vs. 84%, respectively; p = 0.31); however, significantly fewer patients with clear cell histology received adjuvant chemotherapy (35% vs. 67%, respectively; p = 0.02). At 5 years, there were no significant differences in disease-free survival (94% vs. 84%, respectively; p = 0.27), disease-specific survival (100% vs. 92%, respectively; p = 0.20), or overall survival (100% vs. 89%, respectively; p = 0.34). The differences in chemotherapy utilization did not impact pattern of relapse, specifically peritoneal spread (7% vs. 6%, respectively; p = 0.92) or other distant sites (0% vs. 9%, respectively; p = 0.17). CONCLUSIONS: Oncologic outcomes and recurrence patterns of women with stage I-II uterine clear cell carcinoma compared favorably with those of women with serous carcinoma, despite significantly less adjuvant chemotherapy use. Potential reduction in adjuvant therapy in women with clear cell carcinoma should be studied prospectively.
Authors: D Scott McMeekin; Virginia L Filiaci; J Tate Thigpen; Holly H Gallion; Gini F Fleming; William H Rodgers Journal: Gynecol Oncol Date: 2007-07 Impact factor: 5.482
Authors: N Sakuragi; H Hareyama; Y Todo; H Yamada; R Yamamoto; T Fujino; T Sagawa; S Fujimoto Journal: Acta Obstet Gynecol Scand Date: 2000-04 Impact factor: 3.636
Authors: F D Cirisano; S J Robboy; R K Dodge; R C Bentley; H R Krigman; I S Synan; J T Soper; D L Clarke-Pearson Journal: Gynecol Oncol Date: 2000-04 Impact factor: 5.482
Authors: F D Cirisano; S J Robboy; R K Dodge; R C Bentley; H R Krigman; I S Synan; J T Soper; D L Clarke-Pearson Journal: Gynecol Oncol Date: 1999-09 Impact factor: 5.482
Authors: William T Creasman; Matthew F Kohler; Franco Odicino; Patrick Maisonneuve; Peter Boyle Journal: Gynecol Oncol Date: 2004-12 Impact factor: 5.482
Authors: M Thomas; A Mariani; J D Wright; E O S Madarek; M A Powell; D G Mutch; K C Podratz; S C Dowdy Journal: Gynecol Oncol Date: 2007-12-21 Impact factor: 5.482